Document is current
Any future updates will be listed below
-
Authors
Kozicka, Zuzanna https://orcid.org/0000-0003-0085-6565
Suchyta, Dakota J.
Focht, Vivian
Kempf, Georg
Petzold, Georg
Jentzsch, Marius
Zou, Charles
Di Genua, Cristina
Donovan, Katherine A. https://orcid.org/0000-0002-8539-5106
Coomar, Seemon
Cigler, Marko https://orcid.org/0000-0003-1861-7968
Mayor-Ruiz, Cristina
Schmid-Burgk, Jonathan L. https://orcid.org/0000-0003-0988-2487
Häussinger, Daniel https://orcid.org/0000-0002-4798-0072
Winter, Georg E. https://orcid.org/0000-0001-6606-1437
Fischer, Eric S. https://orcid.org/0000-0001-7337-6306
Słabicki, Mikołaj https://orcid.org/0000-0001-6317-9296
Gillingham, Dennis https://orcid.org/0000-0002-3672-8699
Ebert, Benjamin L. https://orcid.org/0000-0003-0197-5451
Thomä, Nicolas H. https://orcid.org/0000-0003-2685-906X
- License Information
-
More Information
Article History
Received: 1 December 2022
Accepted: 24 July 2023
First Online: 7 September 2023
Competing interests
: N.H.T. receives funding from the Novartis Research Foundation and is a scientific advisory board (SAB) member of Monte Rosa Therapeutics and an advisor to Zenith Therapeutics and Ridgeline. B.L.E. has received research funding from Celgene, Deerfield, Novartis and Calico. He has received consulting fees from GRAIL, and he serves on the SABs for and holds equity in Neomorph, TenSixteen Bio, Skyhawk Therapeutics and Exo Therapeutics. E.S.F. is a founder, SAB member and equity holder of Civetta Therapeutics, Lighthorse Therapeutics, Proximity Therapeutics and Neomorph, Inc. (board member). E.S.F. is an equity holder and SAB member for Avilar Therapeutics, Ajax Therapeutics and Photys Therapeutics and a consultant to Novartis, Sanofi, EcoR1 Capital, Odyssey, Astellas and Deerfield. The Fischer lab receives or has received research funding from Novartis, Ajax, Voronoi, Interline, Deerfield and Astellas. D.G. is an SAB member of FoRx therapeutics. The C.M.-R. lab receives research funding from Almirall and Aelin Tx, and C.M.-R. is an SAB member of Nostrum Biodiscovery. G.E.W. is scientific founder and shareholder of Proxygen and Solgate, the Winter laboratory receives research funding from Pfizer. M.S. has received research funding from Calico Life Sciences LLC. G.P. is now an employee of Monte Rosa Therapeutics. C.D.G. is now an employee of VantAI. The remaining authors declare no competing interests.
